China has administered over 31 million doses of COVID-19 vaccines for key groups as of Wednesday.

China granted conditional market approval for its first COVID-19 vaccine on Dec 30, but vaccines in the last stage of clinical trials have been available for emergency use in the country since June. By the end of December, 14 COVID-19 vaccines developed by China were under clinical trials, including five in phase 3, the final trial before a vaccine is approved for market.

The inactivated COVID-19 vaccine, developed by State-owned Sinopharm, which won conditional market approval, is safe and has an efficacy of 79 percent, the company said.